Levodopa/carbidopa/entacapone combination in chronotherapy of Parkinson’s disease
Authors:
- O.S. LevinOLO.S. Levin
- I.G. SmolentsevaISI.G. Smolentseva
- E.A. AleksandrovaEAE.A. Aleksandrova
- A.R. BajtimerovABA.R. Bajtimerov
- D.A. NovotnyjDND.A. Novotnyj
- D.D. PohabovDPD.D. Pohabov
- D.V. PohabovDPD.V. Pohabov
- M.A. RadyukMRM.A. Radyuk
- E.E. VaseninaEVE.E. Vasenina
- O.A. Gan’KInaOGO.A. Gan’KIna
- A.P. Aref’EVaAAA.P. Aref’EVa
- 3 November 2026
- journal article
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (10)
Abstract
Objective. To evaluate the efficacy of the levodopa/carbidopa/entacapone combination in the chronotherapy of Parkinson’s disease (PD). Material and methods. This multicenter study was conducted at seven clinical sites, with 72 patients completing the follow-up period. The efficacy of levodopa/carbidopa/entacapone administration was evaluated in relation to the daily activity profile of levodopa. Patients recorded hourly assessments of «on», «off», and dyskinesia periods in a diary before and after therapy adjustment. The follow-up period lasted one month. Results. Patients misidentified «on» periods in 46% of cases and «off» periods in 35% of cases. The daily profile of levodopa efficacy was heterogeneous: the favorable period occurred in the morning for 40% of patients, in the afternoon for 32%, in the evening for 21%, and in the late evening for 7%. Tailoring levodopa/carbidopa/entacapone administration to the circadian profile improved outcomes in 72% of patients. A morning peak in efficacy predicted high drug sensitivity, while shifting the favorable period to the evening was associated with lower therapy efficacy. Conclusions. Optimizing the timing of antiparkinsonian drug administration in accordance with the circadian rhythm of PD symptoms may enhance therapeutic efficacy. Chronotherapy that incorporates the circadian profile of levodopa efficacy can maximize the benefits of levodopa/carbidopa/entacapone combination therapy.Keywords
This publication has 18 references indexed in Scilit:
- Levodopa/carbidopa/entacapone for the treatment of early Parkinson’s disease: a meta-analysisNeurological Sciences, 2020
- Disease stage dependency of motor and non-motor fluctuations in Parkinson’s diseaseJournal of Neural Transmission, 2019
- Circadian dysfunction and fluctuations in gait initiation impairment in Parkinson’s diseaseExperimental Brain Research, 2018
- MDS clinical diagnostic criteria for Parkinson's diseaseMovement Disorders, 2015
- Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibitionJournal of Neural Transmission, 2014
- Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson’s disease experiencing mild wearing-off: a randomised, double-blind trialJournal of Neural Transmission, 2013
- Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpointAnnals of Neurology, 2011
- Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with wearing-off: efficacy, safety and feasibility—an open-label, 6-week studyJournal of Neural Transmission, 2009
- The development and validation of a short measure of functioning and well being for individuals with Parkinson's diseaseQuality of Life Research, 1995
- Unified Parkinson's disease rating scale characteristics and structureMovement Disorders, 1994